Millendo Therapeutics Inc (NASDAQ:MLND) – Analysts at Wedbush increased their FY2019 earnings estimates for shares of Millendo Therapeutics in a note issued to investors on Wednesday, November 13th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($3.38) per share for the year, up from their previous forecast of ($3.45). Wedbush has a “Buy” rating and a $24.00 price target on the stock. Wedbush also issued estimates for Millendo Therapeutics’ FY2021 earnings at ($3.06) EPS and FY2022 earnings at ($2.29) EPS.
Millendo Therapeutics (NASDAQ:MLND) last issued its quarterly earnings results on Wednesday, November 13th. The company reported ($0.87) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.04).
Shares of Millendo Therapeutics stock opened at $7.92 on Monday. The company has a current ratio of 5.10, a quick ratio of 5.90 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $7.29 and a two-hundred day moving average price of $10.16. Millendo Therapeutics has a 1-year low of $4.56 and a 1-year high of $17.34. The company has a market cap of $104.15 million, a P/E ratio of -0.45 and a beta of 2.70.
Hedge funds have recently added to or reduced their stakes in the company. AWM Investment Company Inc. boosted its position in shares of Millendo Therapeutics by 288.1% during the 2nd quarter. AWM Investment Company Inc. now owns 77,629 shares of the company’s stock worth $897,000 after purchasing an additional 57,629 shares in the last quarter. Strs Ohio bought a new position in shares of Millendo Therapeutics during the 2nd quarter worth about $28,000. Vanguard Group Inc. boosted its position in shares of Millendo Therapeutics by 62.2% during the 2nd quarter. Vanguard Group Inc. now owns 331,285 shares of the company’s stock worth $3,829,000 after purchasing an additional 126,994 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Millendo Therapeutics by 1,830.5% during the 2nd quarter. Wells Fargo & Company MN now owns 14,479 shares of the company’s stock worth $168,000 after purchasing an additional 13,729 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Millendo Therapeutics by 1,738.4% during the 2nd quarter. BlackRock Inc. now owns 468,342 shares of the company’s stock worth $5,414,000 after purchasing an additional 442,866 shares in the last quarter. 50.47% of the stock is currently owned by institutional investors.
Millendo Therapeutics Company Profile
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
Further Reading: When is a capital gain realized?
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.